Stock Price & Analysis

Buy ARWR stock as positive ARO-C3 trial results and strong analyst ratings, including a $80 price target, indicate significant upside potential.

ARWR stock is expected to reach $42 in 2025, driven by positive ARO-C3 trial results showing significant reductions in complement activity and proteinuria, with analysts maintaining a Buy rating. ARWR stock is expected to reach $80 in 2025, as H.C. Wainwright highlights the blockbuster potential of its complement disease franchise, with sustained therapeutic effects supporting less frequent dosing. ARWR stock is expected to reach $38 in 2025, as B. Riley Securities lowers its target, citing valuation concerns despite promising trial data.

The S1 support level for ARWR Stock is $14.44 ,The R1 resistant level for ARWR Stock is $16.46.

As of the end of day on 2025-03-24, the price of ARWR Stock was $15.53.

The target price for ARWR Stock according to analyst rating is 42.22, with the highest price target at 80.00 and the lowest at 21.00. Analysts have a Moderate Buy rating on ARWR Stock overall.

The market cap of ARWR is $2.0B.

Analysis and Insights

Valuation Metrics:

Arrowhead Pharmaceuticals (ARWR) currently exhibits high valuation multiples. The EV/EBITDA ratio stands at 933.77, significantly above industry averages, suggesting a premium valuation. The price-to-book (P/B) ratio is 44.89, indicating investors are paying a high price relative to book value.

Financial Performance:

The company reported a net loss of $173.085 million in Q1 2025, with no positive net income in recent quarters. Revenue remains low at $2.5 million, raising concerns about profitability and growth.

Recent News and Sentiment:

Positive results from the ARO-C3 trial, showing significant reductions in complement activity and proteinuria, were announced. Despite this, ARWR's stock fell 8.72%, possibly due to high expectations or profit-taking. Analysts are divided, with H.C. Wainwright maintaining a Buy rating and $80 target, while others have lowered targets.

Technical Analysis:

The stock's price closed at $15.095 on March 18, 2025, with RSI around 30-33, suggesting oversold conditions. Fibonacci support is at $15.98, but recent price action shows weakness.

Conclusion:

ARWR appears overvalued due to high valuation multiples, consistent losses, and mixed market reaction to positive news. Investors should exercise caution and consider if the stock's price aligns with its fundamentals and growth prospects.

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

ARWR stock is predicted to reach $50-$100 by 2030, driven by its strong pipeline in RNA therapeutics and potential market expansion. The company's focus on innovative treatments positions it for growth in the biotech sector.

ARWR has a total of 525 employees.